Limitations in Surrogate Measures of Insulin Resistance
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
“Insulin resistance” is a loosely defined term that implies a reduction below normal in the ability of insulin to mediate one of its physiological functions. The term is usually applied in the context of glucose regulation, where insulin resistance denotes impairment of insulin-mediated stimulation of glucose removal from the circulation and/or suppression of glucose release into the circulation. Insulin resistance has generated considerable interest in the research community because of its association with such common chronic diseases as obesity, type 2 diabetes, cardiovascular disease, and polycystic ovarian syndrome. Insulin resistance can be quantified directly by two general methods: 1) measurement of glucose utilization and/or glucose production rates during steady-state hyperinsulinemia (glucose clamp technique); or 2) measurement of insulin-mediated changes in glucose disappearance rates after iv glucose challenge (minimal model approach). These methods provide precise quantitative measures of insulin resistance. They are also costly, challenging to perform, and moderately invasive. They are best suited for studies involving tens to hundreds of individuals, although they have been used in studies involving more than a thousand individuals. For larger studies, surrogate measures of insulin resistance have been developed using either fasting blood samples or samples obtained during oral glucose tolerance tests (oGTTs). In general, these surrogates rely on the simple principle that, as insulin resistance increases, insulin levels either rise in compensation or fail to do so, resulting in rising glucose levels. Thus, insulin resistance can be estimated using circulating insulin levels with or without circulating glucose levels. In this issue of JCEM, Lorenzo et al. (1) present a comprehensive evaluation of cross-sectional correlations between 25 of these surrogate measures and either glucose clamp-derived measures of insulin resistance or known cardiovascular risk factors. The measurements were made in a cohort of 272 nondiabetic Finnish adult offspring of individuals with type 2 diabetes. Spearman correlation coefficients between clamp and surrogate measures of insulin resistance were in the range of 0.64–0.77 for surrogates that included at least one plasma insulin level. The best correlations were with surrogates that contained multiple measures of glucose and insulin from oral glucose tolerance tests (r-values of ∼0.75). Only slightly worse were surrogates derived from fasting insulin values (r-values of ∼0.70). Surrogates derived from 2-h insulin values performed worst, but r-values were still approximately 0.65. Correlations between measures of insulin resistance and either metabolic syndrome components or cardiovascular risk were modest (i.e. mostly in the range of 0.15–0.35) and similar in strength for clamp-derived and surrogate measures of insulin resistance. The authors conclude that surrogate measures of insulin resistance are valid and that surrogates derived from fasting measures may be sufficient to adequately measure insulin resistance in clinical and epidemiological studies. What can we learn from this extensive analysis? First, we can learn a main point made by the authors—that in the context of simple correlation coefficients, surrogates based on fasting insulin provide nearly all of the information about insulin resistance that is available from more complex surrogates obtained from oral glucose tolerance tests. Thus, one has to weigh very carefully the small additional correlation that can be obtained against the costs required to perform oGTTs. If oGTTs are being done with measures of insulin for other reasons, then the small additional work of calculating an index like the Matsuda index (2), SIISOGTT (3), Belfiore’s ISI(gly)area (4), or Avignon’s SiM (5) might be worthwhile to get the slightly stronger correlations that these measures provide. On the other hand, conducting oGTTs or measuring insulin from oGTTs specifically for the purpose of estimating insulin resistance may not be worth the cost. The second thing we can learn from the Lorenzo et al. paper (1) is that clamp-derived and surrogate measures of insulin resistance were similarly correlated with metabolic and cardiovascular risks. This observation raises the possibility that insulin resistance is not really the important biological variable that accounts for increased risks of things like the metabolic syndrome and its components, low-grade inflammation, or cardiovascular events. Indeed, most surrogates that contain at least one value for circulating insulin performed as well as or better than a clamp-derived measure of insulin resistance in this context. We don’t really know what accounts for these associations, but it looks like it is not just insulin resistance. Beyond the analysis conducted by Lorenzo et al. (1), we need to ask whether simple correlation analysis is a sufficient basis on which to conclude broadly th
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
Martin Bland, J., & Altman, D. (1986) · The Lancet · doi:10.1016/s0140-6736(86)90837-8 · Cited by 47,965
Lorenzo, C., Haffner, S. M., Stančáková, A., & Laakso, M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1144 · Cited by 92
Cited by
Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome
Moghetti, P., Tosi, F., Bonin, C., Di Sarra, D., Fiers, T., Kaufman, J.-M., Giagulli, V. A., Signori, C., Zambotti, F., Dall'Alda, M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3908 · Cited by 262
Tosi, F., Bonora, E., & Moghetti, P. (2017) · Human Reproduction · doi:10.1093/humrep/dex308 · Cited by 163
“Moreover, surrogate indexes should be validated in each specific setting before they can be appropriately used (Buchanan et al., 2010).”
BackgroundConn, V. S., Koopman, R. J., Ruppar, T. M., Phillips, L. J., Mehr, D. R., & Hafdahl, A. R. (2014) · Journal of Primary Care & Community Health · doi:10.1177/2150131913520328 · Cited by 99
“Surrogate markers of insulin sensitivity are commonly used and recommended for use in some forms of research and clinical practice.(26,27,29) Fasting insulin is a commonly used surrogate marker of insulin resistance.”
MethodAlptekin, H., Çizmecioğlu, A., Işık, H., Cengiz, T., Yildiz, M., & Iyisoy, M. S. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0427-z · Cited by 67
Is cardiorespiratory fitness impaired in PCOS women? A review of the literature
Donà, S., Bacchi, E., & Moghetti, P. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0599-1 · Cited by 20
Metadata
- Authors
- Buchanan, T. A., Watanabe, R. M., & Xiang, A. H.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2010-11
- Volume
- 95
- Issue
- 11
- Pages
- 4874-4876
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2151000106
- Cited by
- 58
- References
- 2
- FWCI
- 1.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Limitations in Surrogate Measures of Insulin Resistance. https://app.cochat.ai/papers/10.1210/jc.2010-2167
- The paper
- Buchanan, T. A., Watanabe, R. M., & Xiang, A. H. (2010). Limitations in Surrogate Measures of Insulin Resistance. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2010-2167
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.